A randomized, controlled study evaluated the effectiveness of perioperative celecoxib administration for pain management after total knee arthroplasty (TKA). Eighty patients were randomly divided into two groups: one received celecoxib (400 mg pre-surgery and 200 mg every 12 hours for five days) along with patient-controlled analgesia (PCA) morphine, while the other received only PCA morphine. The study found that celecoxib significantly reduced postoperative pain scores at 48 and 72 hours, improved active range of motion (ROM) in the first three days, and decreased morphine usage by about 40% compared to the control group. There were no significant differences in blood loss or the need for blood transfusions between the groups. The study concluded that perioperative celecoxib is effective and safe for pain management after TKA, with no increased bleeding risk. The results suggest that celecoxib could be a valuable addition to multimodal analgesia strategies for TKA patients. The study was registered with ClinicalTrials.gov (NCT00598234).A randomized, controlled study evaluated the effectiveness of perioperative celecoxib administration for pain management after total knee arthroplasty (TKA). Eighty patients were randomly divided into two groups: one received celecoxib (400 mg pre-surgery and 200 mg every 12 hours for five days) along with patient-controlled analgesia (PCA) morphine, while the other received only PCA morphine. The study found that celecoxib significantly reduced postoperative pain scores at 48 and 72 hours, improved active range of motion (ROM) in the first three days, and decreased morphine usage by about 40% compared to the control group. There were no significant differences in blood loss or the need for blood transfusions between the groups. The study concluded that perioperative celecoxib is effective and safe for pain management after TKA, with no increased bleeding risk. The results suggest that celecoxib could be a valuable addition to multimodal analgesia strategies for TKA patients. The study was registered with ClinicalTrials.gov (NCT00598234).